Abstract:Combinations of drugs promoting anti-angiogenesis and apoptosis effects are meaningful for cancer therapy. In the present study, dual peptides-modified liposomes were designed by attaching two receptor-specific peptides, specifically low-density lipoprotein receptor-related protein receptor (Angiopep-2) and neuropilin-1 receptor (tLyP-1) for brain tumor targeting and tumor penetration. Vascular endothelial growth factor (VEGF) siRNA and chemotherapeutic docetaxel (DTX) were chosen as the two payloads because VEGF is closely associated with angiogenesis, and DTX can kill tumor cells efficiently. Binding to glioma cells, co-delivery of siRNA and DTX in human glioblastoma cells (U87 MG) and murine brain microvascular endothelial cells (BMVEC), VEGF gene silencing, antiproliferation and anti-tumor effects of the dual peptides-modified liposomes were evaluated in vitro and in vivo. The dual peptides-modified liposomes persisted the binding ability to glioma cells, enhanced the internalization via specific receptor mediated endocytosis and tissue penetration, thus the dual peptides-modified liposomes loading VEGF siRNA and DTX possessed stimulative gene silencing and antiproliferation activity compared with non-modified and single peptide-modified liposomes. The co-delivery research revealed different intracellular behavior of hydrophilic large molecular and lipophilic small molecule, the former involves endocytosis and subsequent escape of endosome/lysosomes, while the latter experiences passive diffusion of lipophilic small drugs after its release. Furthermore, the dual peptides-modified liposomes showed superiority in anti-tumor efficacy, combination of anti-angiogenesis by VEGF siRNA and apoptosis effects by DTX, after both intratumor and system application against mice with U87 MG tumors, and the treatment did not activate system-associated toxicity or the innate immune response. Combination with the dual peptides-guided tumor homing and penetration, the dual peptides-modified liposomes provide a strategy for effective targeting delivery of siRNA and DTX into the glioma cell and inhibition of tumor growth in a synergistic manner.

Doxorubicin-Loaded Liposome with the Function of "Killing Two Birds with One Stone" against Glioma

Glioma Targeting and Blood-Brain Barrier Penetration by Dual-Targeting Doxorubincin Liposomes.

Delivering Sirna and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

A Nanogel with Effective Blood-Brain Barrier Penetration Ability through Passive and Active Dual-Targeting Function

Stable Peptides Mediated Glioma Targeting Drug Delivery

131I-Labeled and DOX-loaded Multifunctional Nanoliposomes for Radiotherapy and Chemotherapy in Brain Gliomas

Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery.

A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy

Peptide-22 and Cyclic Rgd Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming Bbb and Bbtb

A Nanostructure of Functional Targeting Epirubicin Liposomes Dually Modified with Aminophenyl Glucose and Cyclic Pentapeptide Used for Brain Glioblastoma Treatment

Multifunctional Targeting Daunorubicin Plus Quinacrine Liposomes, Modified by Wheat Germ Agglutinin and Tamoxifen, for Treating Brain Glioma and Glioma Stem Cells

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma

Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma

A novel peptide-drug conjugate for glioma-targeted drug delivery

Anti Glioma Effect of Doxorubicin Loaded Liposomes Modified with Angiopep-2

Cell-permeable NF-κB Inhibitor-Conjugated Liposomes for Treatment of Glioma.

Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment.

pH-redox responsive cascade-targeted liposomes to intelligently deliver doxorubicin prodrugs and lonidamine for glioma

Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy.

Tumor-targeting Dual Peptides-Modified Cationic Liposomes for Delivery of Sirna and Docetaxel to Gliomas.